These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 32434734)

  • 1. RNA Splicing and Cancer.
    Wang E; Aifantis I
    Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational landscape of RNA-binding proteins in human cancers.
    Neelamraju Y; Gonzalez-Perez A; Bhat-Nakshatri P; Nakshatri H; Janga SC
    RNA Biol; 2018 Jan; 15(1):115-129. PubMed ID: 29023197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
    Roy Burman D; Das S; Das C; Bhattacharya R
    Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant RNA splicing and therapeutic opportunities in cancers.
    Yamauchi H; Nishimura K; Yoshimi A
    Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative splicing and cancer: a systematic review.
    Zhang Y; Qian J; Gu C; Yang Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
    Lu SX; De Neef E; Thomas JD; Sabio E; Rousseau B; Gigoux M; Knorr DA; Greenbaum B; Elhanati Y; Hogg SJ; Chow A; Ghosh A; Xie A; Zamarin D; Cui D; Erickson C; Singer M; Cho H; Wang E; Lu B; Durham BH; Shah H; Chowell D; Gabel AM; Shen Y; Liu J; Jin J; Rhodes MC; Taylor RE; Molina H; Wolchok JD; Merghoub T; Diaz LA; Abdel-Wahab O; Bradley RK
    Cell; 2021 Jul; 184(15):4032-4047.e31. PubMed ID: 34171309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of splicing in cancer.
    Lee SC; Abdel-Wahab O
    Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors.
    Gibbs ZA; Whitehurst AW
    Trends Cancer; 2018 Oct; 4(10):701-712. PubMed ID: 30292353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Targeting of RNA Splicing in Cancer.
    Bonner EA; Lee SC
    Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia alters splicing of the cancer associated Fas gene.
    Peciuliene I; Vilys L; Jakubauskiene E; Zaliauskiene L; Kanopka A
    Exp Cell Res; 2019 Jul; 380(1):29-35. PubMed ID: 31002816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting splicing abnormalities in cancer.
    Agrawal AA; Yu L; Smith PG; Buonamici S
    Curr Opin Genet Dev; 2018 Feb; 48():67-74. PubMed ID: 29136527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.
    Wickland DP; McNinch C; Jessen E; Necela B; Shreeder B; Lin Y; Knutson KL; Asmann YW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
    Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
    Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
    Bielli P; Pagliarini V; Pieraccioli M; Caggiano C; Sette C
    Cells; 2019 Dec; 9(1):. PubMed ID: 31861467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spliceosomal factor mutations and mis-splicing in MDS.
    Hershberger CE; Daniels NJ; Padgett RA
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
    Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Splicing-factor alterations in cancers.
    Anczuków O; Krainer AR
    RNA; 2016 Sep; 22(9):1285-301. PubMed ID: 27530828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer.
    Liang Z; Kidwell RL; Deng H; Xie Q
    Cancer Biol Med; 2020 Feb; 17(1):9-19. PubMed ID: 32296573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.